Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Quality measures in the design, conduct, and reporting of endoscopic research

Elmunzer BJ, Madhoun M, Cote GA, Cummings LC, Shahidi N, Srivastava N, Essex EA, Scheiman JM, May FP, Yen T, Barkun A, Durkalski-Mauldin V, Dominitz[...]

Premature Ventricular Contractions Ablated via the Left Ventricular Annular Vein: Demonstration of 3 Possible Approaches

Kanzaki Y, Morishima I, Mori S, Shimojo K, Tanaka Y, Yamada T. Premature Ventricular Contractions Ablated via the Left Ventricular Annular Vein: Demonstration of 3[...]